Therapeutic drug monitoring of A77 1726, the active metabolite of leflunomide: serum concentrations predict response to treatment in patients with rheumatoid arthritis.
about
The effect of leflunomide on cycling and activation of T-cells in HIV-1-infected participants.Structure, function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2.Leflunomide for treating rheumatoid arthritis.Semiphysiologically Based Pharmacokinetic Model of Leflunomide Disposition in Rheumatoid Arthritis Patients.Safety and efficacy of leflunomide in primary Sjögren's syndrome: a phase II pilot study.Rheumatic diseases: the effects of inflammation on bone.Genetic polymorphism of CYP1A2 but not total or free teriflunomide concentrations is associated with leflunomide cessation in rheumatoid arthritis.Polymorphisms in cytochrome P450 2C19 enzyme and cessation of leflunomide in patients with rheumatoid arthritis.Chronic Diarrhea Associated with High Teriflunomide Blood ConcentrationSafety evaluation of leflunomide in rheumatoid arthritis.Cytochrome P450 interactions and clinical implication in rheumatology.A Retrospective Study on the Safety and Efficacy of Leflunomide in Dogs.Combination therapy of leflunomide and glucocorticoids for the maintenance of remission in patients with IgG4-related disease: a retrospective study and literature review.Clinical Pharmacokinetic Monitoring of Leflunomide in Renal Transplant Recipients with BK Virus Reactivation: A Review of the Literature.Leflunomide/teriflunomide inhibit Epstein-Barr virus (EBV)- induced lymphoproliferative disease and lytic viral replication.Leflunomide in the treatment of rheumatoid arthritis.Leflunomide in dialysis patients with rheumatoid arthritis--a pharmacokinetic study.Efficacy and safety of weekly leflunomide for the treatment of early rheumatoid arthritis: a randomized, multi-center study.Leflunomide pharmacokinetics after single oral administration to dogs.Mitochondrial dysfunction induced by leflunomide and its active metabolite.Intracellular CD3+ T Lymphocyte Teriflunomide Concentration Is Poorly Correlated with and Has Greater Variability Than Unbound Plasma Teriflunomide Concentration.Putting recommendations into practice: Australian rheumatologists' opinions on leflunomide use in rheumatoid arthritis.The rheumatoid arthritis susceptibility polymorphism PTPN22 C1858T is not associated with leflunomide response or toxicity.
P2860
Q33651140-2446C4FE-2BA2-4195-BFC2-4EACE88CB151Q35015993-EE68B938-DCCC-42A2-94E0-A654AB91ED66Q35048594-3D8DE712-AA42-4160-B0A1-0352C5D65D56Q35861714-ED3F1BC3-3EFF-426F-8FAB-C80E93C72126Q35953478-AD479FD4-013A-452D-B363-FEA3C033BFDEQ36324975-46F113DD-52DB-4E65-8184-13509E5DF27BQ36410232-7FF6D253-4E7E-4EAC-9760-3BEDDBE8AB96Q36633307-DF4BCA90-B701-4C67-9874-AEF44F5385B2Q37208447-F54304B7-3A8B-4B14-A715-4C6642243E2BQ38106213-646C31ED-B987-420B-A498-AB49FB14CFEAQ38219868-5A53063B-6382-48E5-B184-3F64777EE872Q38612043-F9529981-8FEE-48D5-8AE7-3085ED4B9F93Q38891757-579A2A41-4154-4DFF-8C7C-005BB94DE014Q39155699-D69CB7F9-A33D-404E-A94B-29DF83369F00Q40175806-960A8206-82EF-40ED-A61F-64E7FFE0FED9Q43061691-2F004993-98DD-4B88-8DF4-3A319989A132Q43767011-6E4FFDD8-34A1-419C-9421-4DB98C2EF37AQ44017644-5C1A9E39-F1D1-44F5-A74C-B4D7B0DF7A2AQ46305455-00DB79D5-023C-47E3-A22B-7FA055DCC712Q50049868-C76D2490-9210-4792-86FA-CEC92BF80056Q51771540-87413F85-6072-4E1B-A0D8-6590E2C2482DQ53662070-D62CC1C1-6BBE-4E76-8EB2-451ABCC3FF8FQ54336738-D48A7370-CC66-4C96-A244-B7A458E1DAEF
P2860
Therapeutic drug monitoring of A77 1726, the active metabolite of leflunomide: serum concentrations predict response to treatment in patients with rheumatoid arthritis.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Therapeutic drug monitoring of ...... nts with rheumatoid arthritis.
@ast
Therapeutic drug monitoring of ...... nts with rheumatoid arthritis.
@en
type
label
Therapeutic drug monitoring of ...... nts with rheumatoid arthritis.
@ast
Therapeutic drug monitoring of ...... nts with rheumatoid arthritis.
@en
prefLabel
Therapeutic drug monitoring of ...... nts with rheumatoid arthritis.
@ast
Therapeutic drug monitoring of ...... nts with rheumatoid arthritis.
@en
P2093
P2860
P356
P1476
Therapeutic drug monitoring of ...... ents with rheumatoid arthritis
@en
P2093
Brouwers JR
Houtman PM
van Roon EN
van de Laar MA
P2860
P304
P356
10.1136/ARD.2004.025205
P407
P577
2004-09-02T00:00:00Z